180 related articles for article (PubMed ID: 27365203)
41. Impact and cost-effectiveness of the national scale-up of HIV pre-exposure prophylaxis among female sex workers in South Africa: a modelling analysis.
Stone J; Bothma R; Gomez GB; Eakle R; Mukandavire C; Subedar H; Fraser H; Boily MC; Schwartz S; Coetzee J; Otwombe K; Milovanovic M; Baral S; Johnson LF; Venter WDF; Rees H; Vickerman P
J Int AIDS Soc; 2023 Feb; 26(2):e26063. PubMed ID: 36807874
[TBL] [Abstract][Full Text] [Related]
42. Time to Scale Up Preexposure Prophylaxis Beyond the Highest-Risk Populations? Modeling Insights From High-Risk Women in Sub-Saharan Africa.
Grant H; Gomez GB; Kripke K; Barnabas RV; Watts C; Medley GF; Mukandavire Z
Sex Transm Dis; 2020 Nov; 47(11):767-777. PubMed ID: 33044426
[TBL] [Abstract][Full Text] [Related]
43. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
[TBL] [Abstract][Full Text] [Related]
44. Willingness to use HIV prevention methods among vaccine efficacy trial participants in Soweto, South Africa: discretion is important.
Laher F; Salami T; Hornschuh S; Makhale LM; Khunwane M; Andrasik MP; Gray GE; Van Tieu H; Dietrich JJ
BMC Public Health; 2020 Nov; 20(1):1669. PubMed ID: 33160341
[TBL] [Abstract][Full Text] [Related]
45. Cost-effectiveness of community-based strategies to strengthen the continuum of HIV care in rural South Africa: a health economic modelling analysis.
Smith JA; Sharma M; Levin C; Baeten JM; van Rooyen H; Celum C; Hallett TB; Barnabas RV
Lancet HIV; 2015 Apr; 2(4):e159-68. PubMed ID: 25844394
[TBL] [Abstract][Full Text] [Related]
46. Evaluating strategies to improve HIV care outcomes in Kenya: a modelling study.
Olney JJ; Braitstein P; Eaton JW; Sang E; Nyambura M; Kimaiyo S; McRobie E; Hogan JW; Hallett TB
Lancet HIV; 2016 Dec; 3(12):e592-e600. PubMed ID: 27771231
[TBL] [Abstract][Full Text] [Related]
47. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies.
Gomez GB; Borquez A; Case KK; Wheelock A; Vassall A; Hankins C
PLoS Med; 2013; 10(3):e1001401. PubMed ID: 23554579
[TBL] [Abstract][Full Text] [Related]
48. The potential effect of COVID-19-related disruptions on HIV incidence and HIV-related mortality among men who have sex with men in the USA: a modelling study.
Mitchell KM; Dimitrov D; Silhol R; Geidelberg L; Moore M; Liu A; Beyrer C; Mayer KH; Baral S; Boily MC
Lancet HIV; 2021 Apr; 8(4):e206-e215. PubMed ID: 33617783
[TBL] [Abstract][Full Text] [Related]
49. Comparing the impact of increasing condom use or HIV pre-exposure prophylaxis (PrEP) use among female sex workers.
Mukandavire Z; Mitchell KM; Vickerman P
Epidemics; 2016 Mar; 14():62-70. PubMed ID: 26972515
[TBL] [Abstract][Full Text] [Related]
50. When are declines in condom use while using PrEP a concern? Modelling insights from a Hillbrow, South Africa case study.
Grant H; Mukandavire Z; Eakle R; Prudden H; B Gomez G; Rees H; Watts C
J Int AIDS Soc; 2017 Sep; 20(1):21744. PubMed ID: 28953330
[TBL] [Abstract][Full Text] [Related]
51. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
[TBL] [Abstract][Full Text] [Related]
52. Interventions to strengthen the HIV prevention cascade: a systematic review of reviews.
Krishnaratne S; Hensen B; Cordes J; Enstone J; Hargreaves JR
Lancet HIV; 2016 Jul; 3(7):e307-17. PubMed ID: 27365205
[TBL] [Abstract][Full Text] [Related]
53. Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa.
Pretorius C; Stover J; Bollinger L; Bacaër N; Williams B
PLoS One; 2010 Nov; 5(11):e13646. PubMed ID: 21079767
[TBL] [Abstract][Full Text] [Related]
54. HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial.
Hayes R; Ayles H; Beyers N; Sabapathy K; Floyd S; Shanaube K; Bock P; Griffith S; Moore A; Watson-Jones D; Fraser C; Vermund SH; Fidler S;
Trials; 2014 Feb; 15():57. PubMed ID: 24524229
[TBL] [Abstract][Full Text] [Related]
55. The City of Johannesburg can end AIDS by 2030: modelling the impact of achieving the Fast-Track targets and what it will take to get there.
Stuart RM; Fraser-Hurt N; Kerr CC; Mabusela E; Madi V; Mkhwanazi F; Pillay Y; Barron P; Muzah B; Matsebula T; Gorgens M; Wilson DP
J Int AIDS Soc; 2018 Jan; 21(1):. PubMed ID: 29359533
[TBL] [Abstract][Full Text] [Related]
56. HIV research in South Africa: Advancing life.
Gray G; Doherty T; Mohapi L; Coetzee J; Hopkins KL; Malahleha M; Lazarus E; Dietrich J; Pillay-van Wyk V; Laher F
S Afr Med J; 2019 Dec; 109(11b):36-40. PubMed ID: 32252866
[TBL] [Abstract][Full Text] [Related]
57. Vital need to engage the community in HIV control in South Africa.
Hanson S; Zembe Y; Ekström AM
Glob Health Action; 2015; 8():27450. PubMed ID: 26257046
[TBL] [Abstract][Full Text] [Related]
58. The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model.
Hontelez JA; Nagelkerke N; Bärnighausen T; Bakker R; Tanser F; Newell ML; Lurie MN; Baltussen R; de Vlas SJ
Vaccine; 2011 Aug; 29(36):6100-6. PubMed ID: 21703321
[TBL] [Abstract][Full Text] [Related]
59. Preferences for long-acting Pre-Exposure Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment.
Minnis AM; Atujuna M; Browne EN; Ndwayana S; Hartmann M; Sindelo S; Ngcwayi N; Boeri M; Mansfield C; Bekker LG; Montgomery ET
J Int AIDS Soc; 2020 Jun; 23(6):e25528. PubMed ID: 32544303
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
